GlaxoSmithKline Plc agreed to buy biotech company Sierra Oncology for $1.9 billion as the U.K. drugmaker moves to strengthen its lineup of medicines to fight cancer and prepares to spin off its consumer-health unit.
To read the entire story, you must be logged in.
Please log in now or register with us.
